Änderungen von Dokument Pustulosis subcornealis Sneddon-Wilkinson
Zuletzt geändert von Thomas Brinkmeier am 2025/04/25 20:40
<
>
bearbeitet von Thomas Brinkmeier
am 2023/08/04 01:28
am 2023/08/04 01:28
bearbeitet von Thomas Brinkmeier
am 2019/02/02 21:13
am 2019/02/02 21:13
Änderungskommentar:
Es gibt keinen Kommentar für diese Version
Zusammenfassung
-
Objekte (1 geändert, 0 hinzugefügt, 0 gelöscht)
Details
- Wikiderm.EntryClass[0]
-
- Eintrag
-
... ... @@ -65,51 +65,9 @@ 65 65 (% class="Feature" %)Bsp:(%%) Mycoplasma pneumoniae, HIV 66 66 67 67 (% class="Eintrag-2" %) 68 -(% class="Feature" %)DD:(%%) (% class=" Bullet" %)-(%%) (% class="Abbreviation" %)AGEP(%%)68 +(% class="Feature" %)DD:(%%) (% class="Abbreviation" %)AGEP(%%), Dermatitis herpetiformis, eosinophile pustulöse Follikulitis Ofuji, Impetigo contagiosa, Pemphigus foliaceus, Psoriasis pustulosa 69 69 70 -(% class="Ebene-1" %) 71 -(% class="Bullet" %)-(%%) Dermatitis herpetiformis 72 - 73 -(% class="Ebene-1" %) 74 -(% class="Bullet" %)-(%%) eosinophile pustulöse Follikulitis Ofuji 75 - 76 -(% class="Ebene-1" %) 77 -(% class="Bullet" %)-(%%) Impetigo contagiosa 78 - 79 -(% class="Ebene-1" %) 80 -(% class="Bullet" %)-(%%) Pemphigus foliaceus 81 - 82 -(% class="Ebene-1" %) 83 -(% class="Bullet" %)-(%%) anuläre Psoriasis pustulosa 84 - 85 -(% class="Ebene-2" %) 86 -(% class="Feature" %)Bsp:(%%) annular pustular psoriasis 87 - 88 -(% class="Ebene-2" %) 89 -(% class="Feature" %)Lit:(%%) Pediatr Dermatol. 2023 Jan 31. [[http:~~/~~/doi.org/10.1111/pde.15251>>url:http://doi.org/10.1111/pde.15251]] 90 - 91 -(% class="Ebene-1" %) 92 -(% class="Bullet" %)-(%%) Tinea incognito 93 - 94 -(% class="Ebene-2" %) 95 -(% class="Feature" %)Lit:(%%) [[Kalkan, G., Demirseren, D. D, Güney, C. A, & Aktaş, A. (2020). A case of tinea incognito mimicking subcorneal pustular dermatosis. Dermatology Online Journal, 26(2)>>url:https://escholarship.org/uc/item/46g9x55w]] 96 - 97 97 (% class="Eintrag-2" %) 98 -(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) {{pdfbox Datei="Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf" /}} 99 - 100 -(% class="Ebene-1" %) 101 -(% class="Bullet" %)-(%%) Open Access Maced J Med Sci. 2020 Jun 05; 8(T1):12-15. [[https:~~/~~/doi.org/10.3889/oamjms.2020.4870>>url:https://doi.org/10.3889/oamjms.2020.4870]] 102 - 103 -(% class="Ebene-1" %) 104 -(% class="Bullet" %)-(%%) International Journal of Women's Dermatology, Volume 6, Issue 3, 2020, Pages 131-136, ISSN 2352-6475, [[https:~~/~~/doi.org/10.1016/j.ijwd.2020.02.003>>url:https://doi.org/10.1016/j.ijwd.2020.02.003]] 105 - 106 -(% class="Ebene-1" %) 107 -(% class="Bullet" %)-(%%) SAGE Open Med Case Rep. 2019 Jan 30;7:2050313X19826432. [[http:~~/~~/doi.org/10.1177/2050313X19826432>>url:http://doi.org/10.1177/2050313X19826432]] 108 - 109 -(% class="Ebene-1" %) 110 -(% class="Bullet" %)-(%%) JAAD Case Rep. 2022 Jan 21;21:185-188. [[http:~~/~~/doi.org/10.1016/j.jdcr.2021.04.039>>url:http://doi.org/10.1016/j.jdcr.2021.04.039]] 111 - 112 -(% class="Eintrag-2" %) 113 113 (% class="Feature" %)Th:(%%) (% class="Bullet" %)-(%%) lokal 114 114 115 115 (% class="Ebene-2" %) ... ... @@ -116,12 +116,6 @@ 116 116 (% class="Bullet" %)-(%%) Farbstoffe (**[[Antiseptika]]**) 117 117 118 118 (% class="Ebene-2" %) 119 -(% class="Bullet" %)-(%%) Mometasonfuroat 120 - 121 -(% class="Ebene-3" %) 122 -(% class="Feature" %)Lit:(%%) Dermatol Ther. 2021 Nov 27:e15235. [[http:~~/~~/doi.org/10.1111/dth.15235>>url:http://doi.org/10.1111/dth.15235]] 123 - 124 -(% class="Ebene-2" %) 125 125 (% class="Bullet" %)-(%%) Tacalcitol 126 126 127 127 (% class="Ebene-3" %) ... ... @@ -139,12 +139,6 @@ 139 139 (% class="Ebene-5" %) 140 140 (% class="Feature" %)Lit:(%%) (% class="Abbreviation" %)CR(%%) 141 141 142 -(% class="Ebene-2" %) 143 -(% class="Bullet" %)-(%%) Dapson Gel 144 - 145 -(% class="Ebene-3" %) 146 -(% class="Feature" %)Lit:(%%) J Dermatol. 2019 Jun 24. [[http:~~/~~/doi.org/10.1111/1346-8138.14953>>url:http://doi.org/10.1111/1346-8138.14953]] 147 - 148 148 (% class="Ebene-1" %) 149 149 (% class="Bullet" %)-(%%) systemisch 150 150 ... ... @@ -188,12 +188,6 @@ 188 188 (% class="Feature" %)Lit:(%%) Dermatol Ther. 2019 Jan 14:e12818. [[http:~~/~~/doi.org/10.1111/dth.12818>>url:http://doi.org/10.1111/dth.12818]] 189 189 190 190 (% class="Ebene-2" %) 191 -(% class="Bullet" %)-(%%) Apremilast 192 - 193 -(% class="Ebene-3" %) 194 -(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]] 195 - 196 -(% class="Ebene-2" %) 197 197 (% class="Bullet" %)-(%%) Anti-TNF-alpha 198 198 199 199 (% class="Ebene-3" %) ... ... @@ -200,8 +200,14 @@ 200 200 (% class="Feature" %)Stoff:(%%) (% class="Bullet" %)-(%%) **[[Infliximab]]** 201 201 202 202 (% class="Ebene-4" %) 203 -(% class="Feature" %) Lit:(%%)Arch Dermatol 2001; 137: 1571-4, Dermatol Ther. 2022 May 4:e15552. [[http:~~/~~/doi.org/10.1111/dth.15552>>url:http://doi.org/10.1111/dth.15552]]143 +(% class="Feature" %)Phar:(%%) Remicade^^®^^ 204 204 145 +(% class="Ebene-4" %) 146 +(% class="Feature" %)Dos:(%%) 5 mg/kg i.v. 147 + 148 +(% class="Ebene-4" %) 149 +(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4 150 + 205 205 (% class="Ebene-3" %) 206 206 (% class="Bullet" %)-(%%) Adalimumab 207 207 ... ... @@ -209,11 +209,4 @@ 209 209 (% class="Feature" %)Lit:(%%) Ann Dermatol Venereol. 2013 Dec;140(12):797-800 (Frankreich) 210 210 211 211 (% class="Ebene-5" %) 212 -(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%) 213 - 214 -(% class="Ebene-2" %) 215 -(% class="Bullet" %)-(%%) Guselkumab 216 - 217 -(% class="Ebene-3" %) 218 -(% class="Feature" %)Lit:(%%) Int J Dermatol. 2021 Apr;60(4):e153-e154. [[http:~~/~~/doi.org/10.1111/ijd.15311>>url:http://doi.org/10.1111/ijd.15311]] 219 - 158 +(% class="Feature" %)PT:(%%) CR